Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Jun 3, 2026

Accession no.
0001628280-26-040260
Filed
Jun 3, 2026
Trade date
Jun 1, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions and 2 derivative transactions. Open-market sales total $205.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 1, 2026Common StockMOption exerciseAcquired+204$2.39+$487.5621,683Direct
Jun 1, 2026Common StockMOption exerciseAcquired+6,010$2.39+$14,363.927,693Direct
Jun 1, 2026Common StockSSaleDisposed−6,214$20.86F2−$129,624.0421,479Direct
Jun 1, 2026Common StockSSaleDisposed−1,357$20.86F2−$28,307.0243,424Indirect
Jun 1, 2026Common StockSSaleDisposed−1,153$20.86F2−$24,051.5836,908Indirect
Jun 1, 2026Common StockSSaleDisposed−278$20.86F2−$5,799.081,668Indirect
Jun 1, 2026Common StockSSaleDisposed−278$20.86F2−$5,799.081,668Indirect
Jun 1, 2026Common StockSSaleDisposed−278$20.86F2−$5,799.081,668Indirect
Jun 1, 2026Common StockSSaleDisposed−278$20.86F2−$5,799.081,668Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 1, 2026Common StockMOption exerciseDisposed−204$0.00$00Direct
Jun 1, 2026Common StockMOption exerciseDisposed−6,010$0.00$092,431Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $20.470 to $21.175, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)